Therefore, through their potential to alter the balance between the EV surface (i.e., transmembrane) and the released (i.e., soluble) levels of these substrate proteins, ADAM10 and ADAM17 could dramatically influence the docking and uptake of these tumor-derived vesicles and hence their subsequent effects on target cells. The gene discussed is ADAM17; the disease is neoplasm.